

# HSP72 protects against obesity-induced insulin resistance

Jason Chung\*, Anh-Khoi Nguyen<sup>†</sup>, Darren C. Henstridge<sup>‡</sup>, Anna G. Holmes\*, M. H. Stanley Chan\*, Jose L. Mesa\*, Graeme I. Lancaster\*, Robert J. Southgate\*, Clinton R. Bruce\*, Stephen J. Duffy<sup>§</sup>, Ibolya Horvath<sup>¶</sup>, Ruben Mestri<sup>||</sup>, Matthew J. Watt<sup>\*\*</sup>, Philip L. Hooper<sup>††</sup>, Bronwyn A. Kingwell<sup>‡</sup>, Laszlo Vigh<sup>¶</sup>, Andrea Hevener<sup>††§§</sup>, and Mark A. Febbraio<sup>\*||†</sup>

\*Cellular and Molecular Metabolism Laboratory, <sup>‡</sup>Clinical Physiology, and <sup>§</sup>Human Vascular Biology, Baker Heart Research Institute, Prahran, P.O. Box 6492, Victoria 8008, Australia; <sup>†</sup>Department of Medicine, Division of Endocrinology and Metabolism, University of California at San Diego, La Jolla, CA 92093; <sup>||</sup>Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 6726, Szeged, Hungary; <sup>¶</sup>Department of Physiology and the Cardiovascular Institute, Loyola University Medical Center, Maywood, IL 60153; <sup>\*\*</sup>St. Vincent's Institute of Medical Research and the Department of Medicine, University of Melbourne, Fitzroy, Victoria 3065, Australia; <sup>††</sup>Department of Endocrinology, University Colorado Health Sciences Center, Aurora, CO 80045; and <sup>§§</sup>David Geffen School of Medicine, Division of Endocrinology, Diabetes and Hypertension, University of California, Los Angeles, CA 90095

Edited by Michael Karin, University of California at San Diego School of Medicine, La Jolla, CA, and approved December 3, 2007 (received for review June 20, 2007)

**Patients with type 2 diabetes have reduced gene expression of heat shock protein (HSP) 72, which correlates with reduced insulin sensitivity. Heat therapy, which activates HSP72, improves clinical parameters in these patients. Activation of several inflammatory signaling proteins such as c-jun amino terminal kinase (JNK), inhibitor of  $\kappa$ B kinase, and tumor necrosis factor- $\alpha$ , can induce insulin resistance, but HSP 72 can block the induction of these molecules *in vitro*. Accordingly, we examined whether activation of HSP72 can protect against the development of insulin resistance. First, we show that obese, insulin resistant humans have reduced HSP72 protein expression and increased JNK phosphorylation in skeletal muscle. We next used heat shock therapy, transgenic overexpression, and pharmacologic means to overexpress HSP72 either specifically in skeletal muscle or globally in mice. Herein, we show that regardless of the means used to achieve an elevation in HSP72 protein, protection against diet- or obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance was observed. This protection was tightly associated with the prevention of JNK phosphorylation. These findings identify an essential role for HSP72 in blocking inflammation and preventing insulin resistance in the context of genetic obesity or high-fat feeding.**

inflammation | stress proteins | metabolic disorders | JNK | type 2 diabetes

It is now estimated that 10% of the world's population is overweight or obese (1). The myriad of disorders associated with obesity, including insulin resistance, glucose intolerance, and dyslipidemia, eventually lead to the development of pancreatic beta cell failure and overt type 2 diabetes. Despite major scientific advances in our understanding of the molecular pathways leading to insulin resistance and type 2 diabetes made during the last 10–15 years, current therapeutic drugs have had limited success. In the past decade, it has become apparent that obesity is linked to a state of chronic inflammation (2). Inflammation results in the secretion of inflammatory cytokines such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) from macrophages and/or adipocytes, which results in the activation of serine threonine kinases, namely c-jun amino terminal kinase (JNK) and inhibitor of  $\kappa$ B kinase (IKK) in insulin responsive tissues such as adipose tissue, skeletal muscle, and liver (3). It is known that both JNK and IKK phosphorylate IRS-1 on Ser-307, rendering it a poor substrate for the activated insulin receptor (2). In addition, lipid oversupply can lead to increased deposition of lipid species such as diacylglycerol and ceramide, which can also activate JNK and IKK in liver and/or skeletal muscle, leading to insulin resistance (4). The importance of both JNK and IKK in insulin resistance is highlighted by the observation that genetic disruption of these pathways in mice confers protection against obesity induced insulin resistance (5–7).

Heat shock proteins (HSPs) function at the cellular level to protect cells against many chronically and acutely stressful conditions. Subacute activation of HSPs results in stress tolerance and cytoprotection against otherwise lethal exposures to stress-induced molecular damage (8). The induction of the HSPs, therefore, may have broad therapeutic benefits in the treatment of various types of tissue trauma and disease. Small peptides that activate HSPs are currently being investigated as therapies to treat diseases such as cancer, neurodegenerative diseases, and disorders associated with apoptosis (9). Up-regulation of HSP72 by prior heat conditioning or by ectopic expression can markedly block the activation of JNK *in vitro* (10, 11), and liposomal transfer of HSP72 and/or thermal induction of HSP72 prevents NF- $\kappa$ B activation and translocation, TNF- $\alpha$  gene transcription, and subsequent ischemia-induced renal tubular cell apoptosis (12). Importantly, the primary function of HSPs is to serve as molecular chaperones of naïve, aberrantly folded, or mutated proteins, and recent work by Hotamisligil *et al.* (13, 14) has demonstrated that small chaperone peptides that stabilize protein confirmation and facilitate the trafficking of mutant proteins can protect against insulin resistance and type 2 diabetes. Together, these previous data have led us to hypothesize that induction of HSP72 may combat insulin resistance. In this study, we tested this hypothesis by using heat shock therapy, transgenic overexpression, and pharmacologic means to overexpress HSP72 either specifically in skeletal muscle or globally in mice. We show that, regardless of the model used to achieve an elevation in HSP72 protein, protection against diet- or obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance was observed.

Author contributions: B.A.K., L.V., A.H., and M.A.F. designed research; J.C., A.-K.N., D.C.H., S.J.D., I.H., and A.H. performed research; R.M., P.L.H., and L.V. contributed new reagents/analytic tools; J.C., A.-K.N., D.C.H., A.G.H., M.H.S.C., J.L.M., G.I.L., R.J.S., C.R.B., I.H., M.J.W., and A.H. analyzed data; and J.C., A.H., and M.A.F. wrote the paper.

Conflict of interest statement: We obtained the drug BGP-15 from N-Gene R&D Inc., and I.H., L.V., and M.A.F. have a financial interest in this company.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.


<sup>§§</sup>To whom correspondence may be addressed at the †† address. E-mail: ahevener@mednet.ucla.edu.

<sup>||†</sup>To whom correspondence may be addressed at: Cellular and Molecular Metabolism Laboratory, Diabetes and Metabolism Division, Baker Heart Research Institute, P.O. Box 6492, St. Kilda Road Central, VIC, 8008, Australia. E-mail: mark.febrbraio@baker.edu.au.

This article contains supporting information online at [www.pnas.org/cgi/content/full/0705799105/DC1](http://www.pnas.org/cgi/content/full/0705799105/DC1).

© 2008 by The National Academy of Sciences of the USA





**Fig. 3.** HSP72 overexpression in skeletal muscle prevents high-fat-feeding-induced glucose intolerance and insulin resistance, JNK phosphorylation, and impaired insulin signaling. (A) Immunoblot showing enhanced HSP72 expression in mixed gastrocnemius muscle but not epididymal white adipose tissue or liver when comparing HSP72 transgenic (TG) with WT mice. I.p. insulin (B) and glucose tolerance (C) and representative immunoblots and quantification of phosphorylation of JNK (Thr<sup>183</sup>/Tyr<sup>185</sup>)/total JNK in mixed gastrocnemius muscles (D) from WT and HSP72 overexpression (HSP72<sup>+/+</sup>) mice placed on a standard chow (black bars) or high-fat diet (gray bars) for 16 weeks. (E) Representative immunoblots and quantification of phosphorylation of Akt (Thr<sup>308</sup> and Ser<sup>473</sup>) in mixed gastrocnemius muscle excised 2–5 min after i.p. injection of saline (B) or 1.5 units/kg insulin (I) from WT (black bars) and HSP72<sup>+/+</sup> (gray bars) mice after 16 weeks on the HFD. ( $n = 5–9$  mice per group; \*,  $P < 0.05$  WT HFD vs. all other conditions for B–D; \*,  $P < 0.05$  HSP72<sup>+/+</sup> insulin treated vs. all other groups for E.)


curve during the IPGTTs was reduced in HT compared with ST (Fig. 2E).

**HSP72 Overexpression in Skeletal Muscle Prevents High-Fat-Feeding-Induced Elevations in Basal Glucose and Insulin, Glucose Intolerance, and Insulin Resistance.** To investigate whether the reduced HSP72 expression and elevated JNK phosphorylation observed in humans (Fig. 1A–C) was linked and whether up-regulation of HSP72 by HT was indeed the primary mechanism responsible for the improved metabolic control in HT mice on the HFD (Fig. 2B–E), we used skeletal/cardiac muscle-specific HSP72 transgenic mice (HSP72<sup>+/+</sup>) (Fig. 3A) and placed these and control mice (WT) on either a standard chow diet or an HFD for 16 weeks. As expected, the HFD resulted in mild fasting hyperglycemia and marked fasting hyperinsulinemia in WT mice. However, no such effect was seen in HSP72<sup>+/+</sup> mice (SI Fig. 8A and B). IPGTTs and i.p. insulin tolerance tests (IPITTs) were performed on the mice and, consistent with the basal glucose and insulin results, WT mice on the HFD were both insulin resistant and glucose intolerant. In contrast, HSP72<sup>+/+</sup> mice displayed markedly improved insulin and glucose tolerance when placed on an HFD (Fig. 3B and C and SI Fig. 8C and D). These data indicate that HSP72 overexpression in skeletal muscle can protect against the deleterious effects of an HFD in the development of insulin resistance. Because heat therapy conferred protection against insulin resistance in a manner similar to that seen in our HSP72<sup>+/+</sup> animals, we conclude that one mechanism by which heat therapy may improve type 2 diabetic parameters (17) is via the induction of HSP72.

**HSP72 Overexpression in Skeletal Muscle Prevents High-Fat-Feeding-Induced JNK Phosphorylation and Impaired Insulin Signaling.** Because HSP72 overexpression can block JNK and NF $\kappa$ B *in vitro* (10–12), we next tested whether the protection we observed in glucose and insulin tolerance in the HSP72<sup>+/+</sup> mice was associated with decreased activation of these pathways. The phosphorylation of IKK $\alpha$  (Ser<sup>180/181</sup>) was unchanged by diet or treatment in skeletal muscle (data not shown). In contrast, the HFD induced marked phosphorylation of JNK (Thr<sup>183</sup>/Tyr<sup>185</sup>) in WT mice, but this was completely prevented in HSP72<sup>+/+</sup> mice (Fig. 3D). Because JNK is a serine/threonine kinase known to inhibit insulin signaling, we next examined tyrosine phosphorylation of IRS1 and phosphorylation of Akt in skeletal muscle. Although phosphorylation of IRS1 (Tyr<sup>612</sup>) was not increased with insulin stimulation in WT mice on the HFD, it tended ( $P = 0.1$ ) to increase in insulin-stimulated muscle from HSP72<sup>+/+</sup> mice (SI Fig. 8E). Moreover, whereas insulin stimulation did not increase phosphorylation of Akt at two residues critical for activation of this protein (Thr<sup>308</sup>/Ser<sup>473</sup>) in WT mice on the HFD, it markedly phosphorylated Akt at these residues in the HSP72<sup>+/+</sup> mice on the HFD (Fig. 3E). Together, these data suggest that overexpression of HSP72 in skeletal muscle can inhibit the lipid-induced activation of JNK, resulting in better maintained insulin signaling and improved glucose tolerance and insulin action.

**HSP72 Overexpression in Skeletal Muscle Prevents High-Fat-Feeding-Induced Increases in Body Weight and Fat Pad Weight, Which Is Associated with Enhanced Mitochondrial Enzyme Activity.** Whereas the HFD increased body weight in WT, no such effect was seen in HSP72<sup>+/+</sup> mice (Fig. 4A). In addition, we weighed the epididymal fat pads and showed that after 16 weeks on either diet, HSP72<sup>+/+</sup> mice had smaller fat pads relative to WT mice irrespective of diet (Fig. 4B). These effects were not due to hypophagia, because we observed no difference in food intake when comparing strains (Fig. 4C). This observation suggested that the HSP72<sup>+/+</sup> mice may have increased energy expenditure. HSP72 is known to protect cardiac muscle against mitochondrial damage caused by ischemia reperfusion injury (19), whereas heat therapy increases mitochondrial enzyme activity and exercise endurance capacity in rats (20). In addition, we have previously observed a significant positive correlation between the mRNA expression of HSP72 and mitochondrial enzyme activity in human skeletal muscle (15). Given these associations and our observations of smaller fat pads in HSP72<sup>+/+</sup> mice, we examined the oxidative capacity in skeletal muscle of WT and HSP72<sup>+/+</sup> mice by measuring the maximal activities of two important mitochondrial enzymes, citrate synthase (CS) and  $\beta$ -hydroxyacyl-CoA-dehydrogenase ( $\beta$ -HAD). In both extensor digitorum longus (Fig. 4D) and soleus (data not shown) muscles, the maximal activities of these enzymes was higher in HSP72<sup>+/+</sup> compared with WT mice. These data may suggest that the fatty acid oxidative capacity was increased in the skeletal muscles of HSP72<sup>+/+</sup> mice, which may account for the protection against increases in body weight and fat pad mass in HSP72<sup>+/+</sup> mice on the HFD.

**HSP72 Overexpression in Skeletal Muscle Prevents HFD-Induced Phosphorylation of IKK $\alpha$  in Liver, but Increases Circulating Adiponectin Levels.** Previous studies have demonstrated that mice with muscle-specific genetic modifications can display phenotypic alterations in liver (21). In addition, because adipose tissue is known to secrete adipokines that can impair insulin sensitivity in tissue such as liver (22), and because we observed smaller fat pads in our HSP72<sup>+/+</sup> mice, we next examined markers of inflammation and insulin signal transduction in liver. Whereas we observed no difference in phosphorylation of JNK in liver when comparing HSP72<sup>+/+</sup> with WT mice (data not shown), the phosphorylation of IKK $\alpha$  (Ser<sup>180/181</sup>) observed in WT mice on the HFD was abolished in HSP72<sup>+/+</sup> mice (Fig. 4E). Despite this observation, we observed no differences in phosphorylation of Akt (Ser<sup>473</sup>) in insulin stimulated liver



**Fig. 4.** HSP72 overexpression in skeletal muscle prevents high-fat-feeding-induced increases in body weight and activation of IKK in liver and results in reduced fat pad weight, increased mitochondrial oxidative enzyme activity, and increased circulating adiponectin. Body weight (A), epididymal fat pad weight (B), food intake (C), CS and  $\beta$ -hydroxyacyl-CoA-dehydrogenase ( $\beta$ -HAD) in extensor digitorum longus muscle (D), representative immunoblots and quantification of phosphorylation (Ser<sup>180</sup>/Ser<sup>181</sup>) of inhibitor of  $\kappa$ B kinase (IKK)/ $\beta$ -actin in liver (E), and plasma adiponectin (F) from WT and HSP72 overexpression (HSP72<sup>+/+</sup>) mice placed on a standard chow diet (black bars) or an HFD (gray bars) for 16 weeks. ( $n = 4$ – $7$  mice per group; \*,  $P < 0.05$  HFD CON vs. other groups for A and E, \*,  $P < 0.05$  HSP72<sup>+/+</sup> HFD vs. other groups for D; †, main effect for genotype for B, D, and F; ‡, †, main effect for diet for C.)

tissue (data not shown), nor did we observe any difference in the mRNA expression of key hepatic glycogenolytic enzymes PEPCK and G-6-Pase (data not shown) when comparing HSP72<sup>+/+</sup> with WT mice when placed on the HFD. Because these data indicate that a circulatory factor (or factors) may contribute to the differences in IKK $\alpha\beta$  phosphorylation in the liver of HSP72<sup>+/+</sup> and WT mice when placed on a HFD, and because adiponectin is known to down-regulate IKK activity (23), we next examined plasma adiponectin levels. Consistent with our observation of smaller fat pad weight in HSP72<sup>+/+</sup> vs. WT mice irrespective of diet, plasma adiponectin levels were higher in HSP72<sup>+/+</sup> compared with WT mice (Fig. 4F).

#### The Hydroxylamine Derivative BGP-15 Is a Coinducer of HSP72 *In Vitro*.

Hydroxylamine derivatives such as Bimocloamol, Arimocloamol, and BRX-220 are known to be effective in the treatment of wound healing in diabetic complications in rats (24) and in delaying the progression of the fatal neurodegenerative condition amyotrophic lateral sclerosis (ALS) (25). In addition, hydroxylamine derivatives have been shown to improve insulin sensitivity in diet-induced obesity by unknown mechanisms (26, 27). As discussed, transcription of HSP72 is regulated by the activation of HSF-1 (8). Hydroxylamine derivatives are thought to activate HSP72 both via modification of membrane microdomain-associated stress-sensing and -signaling mechanisms (28, 29) and by prolonging the binding of HSF-1 to the respective DNA elements (25, 26, 30). To test whether BGP-15, a hydroxylamine derivative, activated HSP72 via this pathway, we conducted *in vitro* experiments in adipocytes and muscle cells. In preliminary experiments conducted in 3T3-L1 adipocytes, we demonstrated that BGP-15 treatment in the absence of heating cells did not activate HSF-1 or HSP72. However, when cells were heated at 41°C and cotreated with BGP-15, the phosphorylation of HSF1 and expression of HSF1 and HSP72 was markedly increased above that of heat treatment alone (data not shown). Next, fully differentiated L6 myotubes were treated with 50  $\mu$ M BGP-15 or PBS (control) for 30 min and then placed at 42°C for an additional 30, 60, or 120 min. Muscle cells were then placed in a 37°C incubator for a further 7 h before being lysed. Treatment


with BGP-15 increased HSF-1 at 30 min and HSP72 at 60 min but had no effect on HSP90 levels (SI Fig. 9). The data demonstrate that BGP-15 is an inducer of HSF-1/HSP72 *in vitro*, but only in the presence of cotreatment with heat.

#### BGP-15 Activates HSP72 in the Skeletal Muscles of *ob/ob* Mice, Preventing JNK Phosphorylation and Insulin Resistance.

To test the hypothesis that pharmacological activation of HSP72 may be effective in treating obesity-induced insulin resistance, we treated leptin-deficient (*ob/ob*) mice with BGP-15 (15 mg/kg per day in 200  $\mu$ l of saline) or a control (200  $\mu$ l saline) for 15 days by oral gavage. After this time, mice underwent a hyperinsulinemic euglycemic clamp. The 15-day treatment had no effect on body weight in these animals [38.0  $\pm$  1.0 vs. 36.0  $\pm$  0.6 g for BGP-15 and control, respectively (not significant)]. BGP-15 resulted in a marked increase in intramuscular HSP72 protein expression when compared with control-treated animals (Fig. 5A). Accordingly, BGP-15 treatment attenuated JNK phosphorylation (Fig. 5B). Fasting levels of both glucose (Fig. 5C) and insulin (Fig. 5D) were markedly reduced after BGP-15 treatment. In addition, BGP-15 treatment markedly ( $\approx$ 2-fold) increased glucose disposal rate during the clamp (Fig. 5E). Moreover, whereas hyperinsulinemia did not significantly suppress hepatic glucose production (HGP) in control animals during the clamp, there was  $\approx$ 50% suppression of HGP during the clamp in BGP-15-treated animals (Fig. 5F). These data indicate that pharmacological activation of HSP72 can improve insulin sensitivity in a genetic model of obesity in multiple insulin-responsive tissues *in vivo*, and it is likely that the mechanism for this effect is an increased expression of HSP72 via enhanced phosphorylation and expression of HSF-1 leading to a decreased activation of JNK.

#### Discussion

The data presented here provide compelling evidence that HSP72 is a potential target for therapeutic treatment of obesity-induced insulin resistance. Regardless of the means used to achieve an elevation in HSP72 protein, protection against diet or genetic obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance was observed. This protection was tightly associated with the prevention of JNK phosphorylation.



**Fig. 5.** BGP-15 activates HSP72 in the skeletal muscles of *ob/ob* mice, preventing JNK phosphorylation and insulin resistance. Representative immunoblots and quantification of HSP72 (A) and phosphorylation (Thr-183/Tyr-185)/total JNK (B) in quadriceps muscles. Fasting glucose (C), insulin (D), and insulin-stimulated glucose disposal rate (IS-GDR) (E) during a hyperinsulinemic euglycemic clamp. (F) Hepatic glucose production (HGP) without insulin (basal) and after a hyperinsulinemic euglycemic clamp (clamp). All experiments were performed in leptin-deficient (*ob/ob*) mice treated with saline (black bars; control, 200  $\mu$ l of saline) or BGP-15 (gray bars; 15 mg/kg per day in 200  $\mu$ l of saline) for 15 days by oral gavage. ( $n = 5-7$  mice per group; \*,  $P < 0.05$  compared with control; \*†,  $P < 0.05$  compared with basal for BGP-15-treated group.)

These findings identify an essential role for HSP72 in blocking inflammation, which prevents insulin resistance in the context of genetic obesity or high-fat feeding.

The precise mechanism by which HSP72 protects against obesity-induced insulin resistance remains to be elucidated, but our data suggest that HSP72 acts by preventing JNK phosphorylation, which is known to inhibit insulin signal transduction (5), and/or by increasing mitochondrial enzyme activity, because a reduced mitochondrial capacity is tightly associated with insulin resistance (31). Regardless of the model we used, an enhanced HSP72 protein expression was always associated with reduced JNK phosphorylation. However, the data presented here do not provide a mechanism for how HSP72 regulates JNK activation, which is a limitation to this study. We observed no association between HSP72 and JNK *per se* in immunoprecipitation experiments (unpublished observations) and, in all of our experiments reported herein, total JNK protein content was not reduced by increased HSP72 expression. Therefore, the mechanism by which HSP72 can impair JNK activity is not likely to be via degradation of JNK. Rather, recent experiments suggest two potential mechanisms by which HSP72 can down-

regulate JNK. A role for dual leucine zipper-bearing kinase (DLK) as a mechanism by which HSP72 can down-regulate JNK has recently been proposed (32). DLK is a member of the mixed lineage kinase family, which is a known mitogen-activated kinase kinase. DLK is a known upstream activator of JNK, and in this recent study (32) HSP72 was shown to associate with the HSP cochaperone CHIP, a known ubiquitin ligase that negatively regulated DLK expression and activity. Evidence also suggests, however, that the down-regulation of JNK by HSP72 is likely to involve regulation of upstream phosphatases (33). Both the upstream phosphatases MAP kinase phosphatase-1 (MKP-1) (34, 35) and MKP-3 (34) have been shown to be regulated by HSP72, mediating down-regulation of the MAP kinases. Together, it is likely that HSP72 blocks the obesity-induced increase in JNK phosphorylation via decreased DLK and/or increased MKP-1 activity. The observation that CS and  $\beta$ -HAD maximal activity were increased in HSP72<sup>+/+</sup> mice was consistent with our previous studies in humans, in which we showed a correlation between the mRNA expression of HSP72 and mitochondrial enzyme activity in human skeletal muscle (15). HSP72 can enhance mitochondrial capacity and/or function via several mechanisms. It is well known that one major chaperone function of HSP72 is to aid in the mitochondrial import of nuclear encoded proteins via interaction with the mitochondrial protein import receptor protein Tom70 (36). In addition, overexpression of HSP72 in glucose-deprived cells maintains mitochondrial respiratory function and reduces ROS formation (37), the latter which has been recently linked to insulin resistance (38).

The treatment of leptin-deficient (*ob/ob*) mice with BGP-15 for only 15 days up-regulated HSP72 protein expression in skeletal muscle by  $\approx 50\%$  and also resulted in marked reductions in JNK phosphorylation and improvements in insulin resistance in both the liver and peripheral insulin-sensitive tissues. Importantly, hydroxylamine derivatives such as BGP-15 have been reported to be safe and well tolerated at all doses in randomized, placebo-controlled phase IIa clinical trials in patients with ALS (39). Moreover, in a preliminary report, BGP-15 administered orally for 28 days to insulin-resistant, nondiabetic patients was shown to significantly improve whole-body glucose disposal during a hyperinsulinemic euglycemic clamp (40). As discussed, a preliminary report has shown that heat therapy improves the clinical outcomes in patients with type 2 diabetes (17), and here we show that the mechanism for such an outcome is likely to be via up-regulation of HSP72. Hydroxylamines are also shown to act by perturbing membrane hyperstructures, via their highly specific lipid-interactions (28), which is sufficient for the generation and transmission of stress signals to activate HSP genes (29), and via the prolongation of the binding of HSF-1 to the heat shock elements on the DNA (30). Together, these preliminary data in humans (17, 40) and our results with respect to the insulin-sensitizing effect of BGP-15 and heat therapy in our genetic- and diet-induced models of obesity-induced insulin resistance provide a realistic therapeutic strategy to treat obesity-induced insulin resistance.

In summary, we have shown that elevating HSP72 protein by heat treatment, muscle-specific transgenic overexpression, or pharmacological means can protect mice against diet- or obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance. This protection was tightly associated with the prevention of JNK phosphorylation. We have, therefore, identified an essential role for HSP72 in blocking inflammation and preventing insulin resistance in the context of genetic obesity or high-fat feeding.

## Methods

**Human and Animal Experiments.** Methods for human experiments are described in *SI Methods*. For diet-induced obesity studies, we used male WT and transgenic mice (HSP72<sup>+/+</sup>) that had a chimeric transgene that consisted of an inducible HSP72 gene of a rat under a  $\beta$ -actin promoter described in detail elsewhere (41). All experiments were approved by the Royal Melbourne Institute of Technology

Animal Ethics Committee. Experiments always commenced when mice were 8 weeks of age. Control chow diets (5% of total energy from fat) and HFDs (SF03–002; 59% of total energy from fat) were purchased from specialty feeds (Glen Forrest). Animals were given their prescribed diet and water ad libitum and housed in a controlled environment with a 12:12 light–dark cycle.

**Heat Treatment Experiments.** Except for the time course experiment, mice were exposed to heat treatment once per week for a total of 16 weeks. Before heat treatment, mice were anesthetized with sodium pentobarbital (0.05 mg/kg body weight). While unconscious, a rectal thermometer was inserted, and mice were placed in a ventilated plastic container wrapped with an electric heating blanket that was either activated (HT) or not (ST). During HT, body temperature was allowed to rise gradually (10–15 min) to 41.5°C and maintained at this temperature for a total of 15 min by wrapping and unwrapping of the blanket. During the time course experiment, mice were killed immediately, or were allowed to recover at room temperature before being killed at 1, 4, 8, or 24 h. For metabolic testing experiments, mice recovered at room temperature, and experiments were performed at least 72 h after the final HT or ST.

**Glucose and Insulin Tolerance Tests, Insulin Signaling Experiments, Protein Analysis, Oxidative Enzymes, and Plasma Cytokines.** Glucose and insulin tolerance tests were performed after 16 weeks (SI Methods). Proteins were analyzed by SDS/PAGE and immunoblotting (4, 42). C5 and  $\beta$ -HAD in skeletal muscle were assayed spectrophotometrically as described in ref. 15. Plasma adiponectin was assessed by using a Lincoplex mouse serum adiponectin kit (Lincoplex, MADPK-71k-ADPN; Linc Research, Millipore) as described in ref. 42.

**BGP-15 Hyperinsulinemic Euglycemic Clamp Experiments and Cell Culture Experiments.** Male leptin-deficient (*ob/ob*) mice were treated with vehicle (vehicle-treated; 200  $\mu$ l of saline by oral gavage) or BGP-15 (15 mg/kg per day in 200  $\mu$ l of

saline; N-Gene Research Laboratories) for 15 days by oral gavage before undergoing a euglycemic hyperinsulinemic clamp as described in refs. 7 and 21 (SI Methods). Fully differentiated L6 myotubes were treated with 50  $\mu$ M BGP-15 or PBS (control) for 30 min and then placed at 42°C for an additional 30, 60, or 120 min. Muscle cells were then placed in a 37°C incubator for a further 7 h before being lysed and protein analyzed as described previously (4, 42).

**Statistical Analyses.** Results are expressed as the mean  $\pm$  SEM. Data were analyzed for differences by analysis of variance with specific differences located with a Student Newman–Keuls post hoc test, or a Student's *t* test for unpaired samples where appropriate.  $P < 0.05$  was considered to be statistically significant.

**ACKNOWLEDGMENTS.** We thank the human subjects who volunteered for this study and M. Formosa, D. Vizi and K. Ferrier (Baker Heart Research Institute) for their technical assistance. D.C.H and A.G.H were/are supported by an Australian Post Graduate Award, C.R.B. is supported by a Peter Doherty Post-Doctoral Fellowship from the National Health and Medical Research Council of Australia (NHMRC), M.J.W. is supported by an R. Douglas Wright Biomedical Career Development Award (NHMRC), R.J.S is an Australian Post-Doctoral Fellow of the Australian Research Council, S.J.D. is supported by an NHMRC Centre for Clinical Research Excellence Grant to the Alfred and Baker Medical Unit, B.A.K. is a Senior Research Fellow, M.A.F a Principal Research Fellow of the NHMRC, and A.H is supported by National Institutes of Health Grants DK60484 and DK73227. This work was supported, in part, by grants from the NHMRC (Project Grant No. 472650), Diabetes Australia Research Trust (M.A.F), the Agency for Research Fund Management and Research Exploitation (RET OMFB 00067/2005), Marie-Curie Host Fellowship (FP6-MC-TOK-2004-003091) and the Hungarian National Scientific Research Foundation (OTKA NK 68379) (L.V and I.H). BGP-15 was provided by N-Gene R&D Inc. (U.S.).

- Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. *JAMA* 288:1723–1727.
- Hotamisligil GS (2006) Inflammation and metabolic disorders. *Nature* 444:860–867.
- Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. *J Clin Invest* 115:1111–1119.
- Watt MJ, Hevener A, Lancaster GI, Febbraio MA (2006) Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of JNK in peripheral tissues. *Endocrinology* 147:2077–2085.
- Hirosumi J, et al. (2002) A central role for JNK in obesity and insulin resistance. *Nature* 420:333–336.
- Cai D, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med* 11:183–190.
- Arkan MC, et al. (2005) IKK-beta links inflammation to obesity-induced insulin resistance. *Nat Med* 11:191–198.
- Morimoto RI (1993) Cells in stress: Transcriptional activation of heat shock genes. *Science* 259:1409–1410.
- Westerheide SD, Morimoto RI (2005) Heat shock response modulators as therapeutic tools for diseases of protein conformation. *J Biol Chem* 280:33097–33100.
- Gabai VL, et al. (1997) Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance. *J Biol Chem* 272:18033–18037.
- Park HS, Lee JS, Huh SH, Seo JS, Choi EJ (2001) Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. *EMBO J* 20:446–456.
- Meldrum KK, et al. (2003) Liposomal delivery of heat shock protein 72 into renal tubular cells blocks nuclear factor-kappaB activation, tumor necrosis factor-alpha production, and subsequent ischemia-induced apoptosis. *Circ Res* 92:293–299.
- Ozcan U, et al. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* 306:457–461.
- Ozcan U, et al. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. *Science* 313:1137–1140.
- Bruce CR, Carey AL, Hawley JA, Febbraio MA (2003) Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: Evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. *Diabetes* 52:2338–2345.
- Kurucz I, et al. (2002) Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance. *Diabetes* 51:1102–1109.
- Hooper PL (1999) Hot-tub therapy for type 2 diabetes mellitus. *New Eng J Med* 341:924–925.
- He B, Meng Y-H, Mivechi NF (1998) Glycogen synthase kinase 3 $\beta$  and extracellular signal-regulated kinase inactivate heat shock transcription factor 1 by facilitating the disappearance of transcriptionally active granules after heat shock. *Mol Cell Biol* 18:6624–6633.
- Suzuki K, et al. (2002) Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. *Circulation* 106:1270–1276.
- Chen HW, Chen SC, Tsai JL, Yang RC (1999) Previous hyperthermic treatment increases mitochondria oxidative enzyme activity and exercise capacity in rats. *Kaohsiung J Med Sci* 15:572–580.
- Hevener A, et al. (2003) Muscle-specific Pparg deletion causes insulin resistance. *Nat Med* 9:1491–1497.
- Scherer PE (2006) Adipose tissue: From lipid storage compartment to endocrine organ. *Diabetes* 55:1537–1545.
- Wu X, et al. (2007). Adiponectin suppresses I $\kappa$ B Kinase activation induced by tumor necrosis factor- $\alpha$  or high glucose in endothelial cells: role of cAMP and AMP Kinase signaling. *Am J Physiol Endocrinol Metab* 293:E1836–E1844
- Vigh L, et al. (1997) Bimoclolomol: A nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. *Nat Med* 3:1150–1154.
- Kieran D, et al. (2004) Treatment with arimoclolomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. *Nat Med* 10:402–405.
- Kurthy M, et al. (2002) Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. *Ann NY Acad Sci* 967:482–489.
- Sebokova E, et al. (2002) Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance. *Ann NY Acad Sci* 967:424–430.
- Török Z, et al. (2003) Heat shock protein co-inducers with no effect on protein denaturation specifically modulate the membrane lipid phase. *Proc Natl Acad Sci USA* 100:3131–3136.
- Vigh L, Horvath I, Maresca B, Harwood JL (2007) Can the stress protein response be controlled by “membrane-lipid therapy”? *Trends Biochem Sci* 32:357–363.
- Hargitai J, et al. (2003) Bimoclolomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. *Biochem Biophys Res Commun* 307:689–695.
- Lowell BB, Shulman GI (2005) Mitochondrial dysfunction and type 2 diabetes. *Science* 307:384–387.
- Daviau A, et al. (2006) Down-regulation of the mixed-lineage dual leucine zipper-bearing kinase by heat shock protein 70 and its co-chaperone CHIP. *J Biol Chem* 281:31467–31477.
- Yaglom J, O’Callaghan-Sunol C, Gabai V, Sherman MY (2003) Inactivation of dual-specificity phosphatases is involved in the regulation of extracellular signal-regulated kinases by heat shock and hsp72. *Mol Cell Biol* 23:3813–3824.
- Meriin AB, et al. (1999) Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72. *Mol Cell Biol* 19:2547–2555.
- Lee KH, et al. (2005) Preheating accelerates mitogen-activated protein (MAP) kinase inactivation post-heat shock via a heat shock protein 70-mediated increase in phosphorylated MAP kinase phosphatase-1. *J Biol Chem* 280:13179–13186.
- Young JC, Hoogenraad NJ, Hartl FU (2003) Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. *Cell* 112:41–50.
- Ouyang YB, Xu LJ, Sun YJ, Giffard RG (2006) Overexpression of inducible heat shock protein 70 and its mutants in astrocytes is associated with maintenance of mitochondrial physiology during glucose deprivation stress. *Cell Stress Chaperones* 11:180–186.
- Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* 440:944–948.
- Northeast ALS Consortium (2005) *NEALS Clinical Trials*. Available at www.alnsconsortium.org/trials.html. Accessed October 11, 2006.
- Kolonics A, et al. (2006) BGP-15, a new type of insulin sensitizer. *Diabetes* 55(Suppl 1):A-483 (abstr).
- Marber MS, et al. (1995) Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. *J Clin Invest* 95:1446–1456.
- Watt MJ, et al. (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. *Nat Med* 12:541–548.